Key facts
- AOA (Diagnostic Equipment)’s last known valuation is $65.0M (Oct 2025).
- It has raised $56.5M across 1 recorded rounds; the latest was Seed Round ($2.5M) in May 2021.
- Notable investors include Creative Destruction Lab, MassChallenge, Pioneer Fund, Mana Ventures, Impact Assets — 54 tracked in total.
- Status: Privately Held (backing).
- ·Post-money valuations for all 1 rounds
- ·The complete investor list — 54 names
- ·Watchlist + deal alerts for AOA (Diagnostic Equipment)
Funding rounds
1 roundsAbout AOA (Diagnostic Equipment)
Developer of an early disease detection platform designed to revolutionize early-stage cancer detection for women. The company offers a multi-omics approach powered by glycolipids, tumor marker gangliosides, lipids, and proteins, enabling healthcare providers to set a new gold standard in early cancer diagnostics and improve life-saving outcomes.
- Industry
- Diagnostic Equipment
- Sector
- Healthcare
- HQ
- Denver, CO, United States
- Founded
- 2020
- Employees
- 23
- Website
- aoadx.com/
- Ownership
- Privately Held (backing)
AOA (Diagnostic Equipment) doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in AOA (Diagnostic Equipment) shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on AOA (Diagnostic Equipment) in its N-PORT filings yet. We sweep new filings monthly.